Cash Flow Statement

Acquisitions Amortization Amortization Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Cellebrite DI (CLBT) Depreciation & Amortization (CF) (2022 - 2023)

Cellebrite DI's Depreciation & Amortization (CF) history spans 2 years, with the latest figure at $1.7 million for Q4 2023.

Quarterly Depreciation & Amortization (CF) rose 3.44% to $1.7 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Sep 2024, down 45.94% year-over-year, with the annual reading at $11.9 million for FY2025, 11.88% up from the prior year.
Depreciation & Amortization (CF) came in at $1.7 million for Q4 2023, up from $1.5 million in the prior quarter.
In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.7 million in Q4 2023 to a low of $1.5 million in Q3 2023.